Aktuellt
SENASTE
In the fourth quarter, Cantargia continued with its ongoing programs and strategy. The share price reached a historical low but has begun to recuperate since early January 2023. In February, after the end of Q4, solid efficacy results were presented from the phase I part of TRIFOUR in triple-negative breast cancer.
LÄS MER
